Articles > Medtronic PLC Delivers Record Revenue Growth and Strategic Innovations in Q4 2026
- Medtronic reports $9.8 billion in revenue for Q4, up 9.9% reported and 6.6% organically
- Adjusted EPS reaches $1.55 for Q4
- Strong Q4 results lead to an optimistic FY27 growth outlook
- Medtronic beats Q4 earnings and revenue estimates, leading to stock rise
- Company submits 510(k) filings to expand Hugo™ robotic-assisted surgery system
Medtronic PLC has reported record revenue growth and unveiled strategic innovations in its Q4 2026 earnings call. The company posted $9.8 billion in revenue for the fourth quarter, reflecting a 9.9% increase reported and a 6.6% growth organically. Additionally, the adjusted earnings per share (EPS) for Q4 reached $1.55, surpassing expectations.
Following a robust fiscal Q4 performance, Medtronic shares have been on the rise, driven by an optimistic growth outlook for fiscal year 2027. The company's strong results in the fourth quarter surpassed expectations, fueling investor confidence.
Medtronic's performance in Q4 exceeded estimates, with revenue and earnings beating expectations. The company's focus on Cardiovascular strength and growth in Cardiac Ablation contributed to the positive results. Additionally, the guidance for FY27 points towards further growth and success.
Market sentiment received a boost with positive jobs data, contributing to Medtronic's strong performance in Q4. The company's top-line performance in the last quarter was described as the best in a decade, led by growth in various segments including cardiovascular, diabetes, and medical-surgical products.
Medtronic has submitted 510(k) filings to expand the use of its Hugo™ robotic-assisted surgery system, targeting general and gynecologic specialties in the United States. The company is also making strategic investments in cardiac ablation technologies to support future growth and innovation in the segment.
Medtronic's fiscal year 2026 results showcase the company's highest revenue growth in 10 years. With disciplined execution and portfolio strength, Medtronic is well-positioned for continued success heading into fiscal year 2027. The company's commitment to driving growth through innovative technologies and strategic investments underscores its dedication to advancing healthcare solutions.
For more information:
Up/Down Rally Price Distribution Analyst Recommendations Earning Price Impact Analysis Seasonality
Medtronic PLC Delivers Record Revenue Growth and Strategic Innovations in Q4 2026
By KlickAnalytics Data Insights | June 3, 2026 08:01PM ET
Key Points
- Medtronic reports $9.8 billion in revenue for Q4, up 9.9% reported and 6.6% organically
- Adjusted EPS reaches $1.55 for Q4
- Strong Q4 results lead to an optimistic FY27 growth outlook
- Medtronic beats Q4 earnings and revenue estimates, leading to stock rise
- Company submits 510(k) filings to expand Hugo™ robotic-assisted surgery system
Medtronic PLC has reported record revenue growth and unveiled strategic innovations in its Q4 2026 earnings call. The company posted $9.8 billion in revenue for the fourth quarter, reflecting a 9.9% increase reported and a 6.6% growth organically. Additionally, the adjusted earnings per share (EPS) for Q4 reached $1.55, surpassing expectations.
Following a robust fiscal Q4 performance, Medtronic shares have been on the rise, driven by an optimistic growth outlook for fiscal year 2027. The company's strong results in the fourth quarter surpassed expectations, fueling investor confidence.
Medtronic's performance in Q4 exceeded estimates, with revenue and earnings beating expectations. The company's focus on Cardiovascular strength and growth in Cardiac Ablation contributed to the positive results. Additionally, the guidance for FY27 points towards further growth and success.
Market sentiment received a boost with positive jobs data, contributing to Medtronic's strong performance in Q4. The company's top-line performance in the last quarter was described as the best in a decade, led by growth in various segments including cardiovascular, diabetes, and medical-surgical products.
Medtronic has submitted 510(k) filings to expand the use of its Hugo™ robotic-assisted surgery system, targeting general and gynecologic specialties in the United States. The company is also making strategic investments in cardiac ablation technologies to support future growth and innovation in the segment.
Medtronic's fiscal year 2026 results showcase the company's highest revenue growth in 10 years. With disciplined execution and portfolio strength, Medtronic is well-positioned for continued success heading into fiscal year 2027. The company's commitment to driving growth through innovative technologies and strategic investments underscores its dedication to advancing healthcare solutions.
For more information:
Disclaimer: the above is a summary showing certain market information. KlickAnalytics is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from various resources and more. Communications displaying market prices, data and other information available in this post are meant for purely for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.